Alzheimer’s disease (AD) is a chronic neurodegenerative disease, which can affect cognitive competence and learning capacity. (1) Also, the number of the affected people is remarkably increasing worldwide. (2,3) As indicators of the disease state, biomarkers play a crucial role in early diagnosis, prognosis, or response to treatment of cancer. (4) Advances in therapeutic strategies for the AD and the development of the condition would dramatically relieve the global burden. (5) The amyloid-beta protein is also referred to as Aβ, which consists of 36–43 amino acids, and is the key component of the amyloid plaques in the brains of Alzheimer patients. (6) Aβ is also discovered to be implicated in biological regulation and psychological mechanisms. (7−10) In addition, Aβ levels have been deemed to be connected with a number of cancers. (11,12) Therefore, constructing a sensitive biosensing platform for Aβ is of significance in early diagnosis and treatment of the disease.